Treatment of the antiphospholipid antibody syndrome: Progress in the last five years?
- Michelle Petri MD, MPH
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains highintensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful “proving ground” of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.
References and Recommended Reading
Rosove MH, Brewer PMC: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303–308.PubMed
Bern MM, Wallach SR, Bothe Jr. A, et al.: Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990, 112(6):423–428.PubMed
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk: the Medical Research Council’s General Practice Research Framework. Lancet 1998, 351:233–241.
Krnic-Barrie S, O’Connor CR, Looney SW, et al.: A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997, 157(18):2101–2108. A retrospective case series that suggests that high-intensity warfarin may not be necessary.PubMedCrossRef
Prandoni P, Simoni P, Girolami A: Antiphospholipid antibodies, recurrent thromboembolism and intensity of oral anticoagulation. Thromb Haemost 1996, 75:859.PubMed
Rance A, Emmerich J, Fiessinger J-N: Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost 1997, 77:221–222.PubMed
Petri M: Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25:191–193.PubMed
Cowchock FS, Reece EA, Balaban D, et al.: Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992, 166:1318–1323. The classic clinical trial that found that heparin/aspirin and prednisone/aspirin are equally effective, but heparin/aspirin is associated with fewer side-effects.PubMed
Salafia CM, Parke AL: Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Rheum Dis Clin N Am 1997, 23:85–98.CrossRef
Rosove MH, Tabsh K, Wasserstrum N, et al.: Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990, 75:630–634.PubMed
Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997, 314(7076):253–257.
Ginsburg KS, Liang MH, Newcomer L, et al.: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Int Med 1992, 117:997–1002.PubMed
Petri M, Lakatta C, Magder L, Goldman DW: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254–259. Prednisone increases the total serum cholesterol, mean arterial pressure, and weight. Hydroxychloroquine lowers total serum cholesterol.PubMedCrossRef
Robbins DL, Leung S, Miller-Blair DJ, Ziboh V: Effect of anticardiolipin/ beta-2 glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998, 25:51–56.PubMed
Asherson RA, Piette J-C: The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996, 5:414–417. A retrospective case series in which patients who were plasmapheresed were more likely to survive.PubMed
Weisman MH, Bluestein HG, Berner CM, de Haan HA: Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997, 24(2):314–318.PubMed
Brodsky RA, Petri M, Smith BD, et al.: Immunoblative highdose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Int Med 1998, 129:1031–1035. High-dose cyclophosphamide—without stem cell transplantation— may be sufficient to lead to long-term remissions in some patients.PubMed
Brodsky RA, Sensenbrenner LL, Jones RJ: Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996, 87:491–494.PubMed
Harris EN, Pierangeli SS: Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol Suppl 1998, 107:97–102.PubMed
Birdsall MA, Lockwood GM, Ledger WL, et al.: Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod 1996, 11(6):1185–1189.PubMed
Sher G, Matzner W, Feinman M, et al.: The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am J Reprod Immunol 1998, 40:74–82.PubMed
Fishman P, Falach-Vaknin E, Sredni B, et al.: Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol 1995, 22:1086–1090.PubMed
Piette J-C: 1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a ‘mission impossible’? Lupus 1996, 5:354–363.PubMed
Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42(7):309–311.CrossRef
- Treatment of the antiphospholipid antibody syndrome: Progress in the last five years?
Current Rheumatology Reports
Volume 2, Issue 3 , pp 256-261
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Johns Hopkins University School of Medicine, 1830 E. Monument Street, Suite 7500, 21205, Baltimore, MD, USA